Your trusted source for investing success

Tag: Underwritten Public Offering

Tech Forecast and Promising Tech Stocks To Buy in 2017

Learn about breakthrough technology about to impact lives around the globe. We cover the entire industry in our FREE investor’s report.   Gain Access

Catalyst Biosciences Announces Closing of Public Offering of Common Stock

Catalyst Biosciences (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications (the Company), today announced the closing of an underwritten public offering of 3,382,352 shares of its common stock, offered at a price of $34.00 per share to the public, which includes the exercise in

Amicus Therapeutics Announces Public Offering of Common Stock

Amicus Therapeutics (Nasdaq:FOLD) announced it has commenced a $250 million underwritten public offering of its common stock. J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC are acting as joint lead book-running managers, Cowen and Leerink Partners LLC are acting as co-book-running managers, and BofA Merrill Lynch is acting

Avid Bioservices Announces Proposed Offering of Common Stock

Avid Bioservices (NASDAQ:CDMO) announced that it has commenced an underwritten public offering of its common stock. Avid Bioservices also intends to grant the underwriter a 30-day option to purchase from it up to an additional 15% of the shares of common stock offered in the public offering to cover over-allotments, if

Avinger Announces Pricing of $18 Million Underwritten Public Offering

Avinger (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the pricing of an underwritten public offering of Series B convertible preferred stock, together with warrants, for gross proceeds of $18.0 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Avinger.

As

Pieris Pharmaceuticals Announces Public Offering of Common Stock

Pieris Pharmaceuticals (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. Pieris intends to grant the underwriters a 30-day option to

Catalyst Biosciences Announces Proposed Public Offering of Common Stock

Catalyst Biosciences (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications (the Company), today announced that it is offering, subject to market conditions, shares of its common stock in an underwritten public offering.

As quoted in the press release:
The Company anticipates using the net proceeds from

Affimed Announces Proposed Public Offering of Common Stock

Affimed (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that it has commenced an underwritten public offering of its common shares. The company expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of

Adverum Biotechnologies Announces Closing of $69 Million Public Offering

Adverum Biotechnologies (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced the closing of its previously announced underwritten public offering of its common stock.  Adverum Biotechnologies sold 10,222,235 shares of its common stock, including 1,333,335 shares pursuant to the full exercise

Viveve Announces Closing of Public Offering of Shares of Common Stock

Viveve Medical (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock at a public offering price of $3.00 per share, including shares of common stock issued upon the full exercise by

miRagen Therapeutics Prices Public Offering of Common Stock

miRagen Therapeutics (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the pricing of its previously announced underwritten public offering of 7,000,000 shares of its common stock at a public offering price of $5.50 per share.

As quoted in the press release:
miRagen intends to

Gemphire Announces Pricing of $22 Million Public Offering of Common Stock

Gemphire Therapeutics (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia, Non Alcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis, announced the pricing of its previously announced underwritten public offering of 3,142,858 shares of its common stock at a public offering price of $7.00

miRagen Therapeutics Announces Proposed Public Offering of Common Stock

miRagen Therapeutics (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced that it intends to offer for sale 7,000,000 shares of its common stock in an underwritten public offering.

As quoted in the press release:
miRagen intends to use the net proceeds from this offering for

CymaBay Announces Closing of Public Offering of Common Stock

CymaBay Therapeutics (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced the closing of its previously announced underwritten public offering of its common stock.

As quoted in the press release:
CymaBay sold 13,340,000 shares of its common stock in the offering,

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
 
Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
5 Top Weekly NASDAQ Tech Stocks: Index on Pace for Best Week in 6 Years

URL: https://investingnews.com/daily/tech-investing/data-investing/weekly-nasdaq-tech-stocks/